stockrowElanco Animal Health Incorporated
ELAN Healthcare Drug Manufacturers Specialty & Generic
Elanco Animal Health Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $4.7 billion, up 6.22% from fiscal 2024.
- Revenue
- +10.2%
- EPS
- +450.0%
- Free cash flow
- +35.6%
- Total debt
- −6.91%
Quarter to June 2026, against a year earlier
Follow ELAN
Alert me
Elanco Animal Health Incorporated (ELAN) Shares outstanding
Elanco Animal Health Incorporated's shares outstanding at the end of fiscal 2025 was $496.4M, unchanged from fiscal 2024. At the end of the quarter to 30 June 2026 it was $505.9M. Over the past ten years it has ranged from $293.3M (fiscal 2017) to $497.3M (fiscal 2024); the current reading is higher than 90% of that period. Elanco Animal Health Incorporated ranks 6th of 81 Drug Manufacturers Specialty & Generic companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $496.4M | (0.18%) |
| FY2024 | $497.3M | 1.02% |
| FY2023 | $492.3M | 0.82% |
| FY2022 | $488.3M | 0.23% |
| FY2021 | $487.2M | 10.38% |
| FY2020 | $441.4M | 19.20% |
| FY2019 | $370.3M | 18.04% |
| FY2018 | $313.7M | 6.96% |
| FY2017 | $293.3M | 0.00% |
| FY2016 | $293.3M | — |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Jun 2026 | $505.9M | (0.02%) |
| Mar 2026 | $506.0M | 1.93% |
| Dec 2025 | $496.4M | (0.08%) |
| Sep 2025 | $496.8M | (0.66%) |
| 31 more quarters | Free account |
Against its own ten years
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| VTRS Viatris Inc. compare | $1.2B |
| RDY Dr. Reddy's Laboratories Ltd compare | $833.3M |
| ELAN Elanco Animal Health Incorporated | $505.9M |
| AMRX AMNEAL PHARMACEUTICALS, INC. compare | $335.7M |
| HIMS Hims & Hers Health, Inc. compare | $231.7M |
| ALKS Alkermes plc compare | $176.4M |
| NBIX Neurocrine Biosciences, Inc. compare | $105.2M |
| KNSA Kiniksa Pharmaceuticals International, plc compare | $84.9M |
| LNTH Lantheus Holdings, Inc. compare | $68.4M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item
More on ELAN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement